Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Catabasis Pharma (CATB)

1.81 0.03 (1.69%)

04-18 16:00

Open:

1.76

Pre. Close:

1.78

High:

1.85

Low:

1.75

Volume:

236,955

Market Cap:

53M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

1.851 - 1.862

1.862 - 1.873

Low:

1.725 - 1.737

1.737 - 1.749

Close:

1.79 - 1.809

1.809 - 1.828

Technical analysis  (as of: 2018-04-18 4:38:49 PM)

Overall:

      

Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 2.32     One year: 2.55

Support:

Support1: 1.68    Support2: 1.40

Resistance:

Resistance1: 1.99    Resistance2: 2.18

Pivot:

1.79

Moving Averages:

MA(5): 1.81     MA(20): 1.83

MA(100): 1.69     MA(250): 1.62

MACD:

MACD(12,26): -0.01     Signal(12,26,9):

%K %D:

%K(14,3): 45.25     %D(3): 40.87

RSI:

RSI(14): 49.09

52-Week:

High: 3.78  Low: 1.09  Change(%): 19.1

Average Vol(K):

3-Month: 100817  10-Days 15943

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CATB has closed below upper band by 32.9%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to CATB's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-04-18T08:00:00-04:00
Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting

2018-04-17T16:01:00-04:00
Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy

2018-04-12T09:15:11-04:00
Dosing underway in early-stage study of Pfizer's DMD candidate

2018-03-20T08:00:00-04:00
Catabasis Pharmaceuticals to Present at Oppenheimer's 28th Annual Healthcare Conference

2018-03-15T23:00:49-04:00
Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2017 Results - Earnings Call Transcript

2018-03-15T17:37:41-04:00
After Hours Gainers / Losers (3/15/2018)

2018-03-15T16:27:03-04:00
Catabasis Pharmaceuticals beats by $0.07, beats on revenue

2018-03-15T16:10:00-04:00
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

29.04

Shares Float (M)

28.53

% Held by Insiders

2.20

% Held by Institutions

24.10

Shares Short (K)

401

Shares Short Prior Month (K)

229

Stock Financials

EPS

-1.280

EPS Est. Current Year

-1.390

EPS Est. Next Year

-1.100

EPS Est. Next Quarter

-0.330

Forward EPS

-1.221

Book Value (p.s.)

4.480

PEG Ratio

Profit Margin

Operating Margin

-5418.80

Return on Assets (ttm)

-94.2

Return on Equity (ttm)

-133.9

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.732

Qtrly Earnings Growth

Operating Cash Flow (M)

-26.84

Levered Free Cash Flow (M)

-16.61

atoplab.com

Valuation

P/E

-1.41

P/E Growth Ratio

0.02

P/BV

0.40

P/S

2628119808.00

P/CF

-1.96

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.